Haemonetics Corp: Form 10-Q for the period ended Sep 28, 2024
Filed with the SEC on Nov 7, 2024 and accepted by EDGAR at Nov 7, 2024, 06:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-06-30 to 2024-09-28 | $345.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-03-31 to 2024-09-28 | $681.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-06-30 to 2024-09-28 | $158.1m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2024-03-31 to 2024-09-28 | $319.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-06-30 to 2024-09-28 | $187.4m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-03-31 to 2024-09-28 | $362.4m | us-gaap:GrossProfit |
| Research and development | 3 months2024-06-30 to 2024-09-28 | $16.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-03-31 to 2024-09-28 | $31.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-06-30 to 2024-09-28 | $106.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-03-31 to 2024-09-28 | $215.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-06-30 to 2024-09-28 | $51.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-03-31 to 2024-09-28 | $91.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-06-30 to 2024-09-28 | $10.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-03-31 to 2024-09-28 | $19.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-06-30 to 2024-09-28 | $33.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-03-31 to 2024-09-28 | $72.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-06-30 to 2024-09-28 | $0.66 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-03-31 to 2024-09-28 | $1.40 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-06-30 to 2024-09-28 | $0.66 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-03-31 to 2024-09-28 | $1.42 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-06-30 to 2024-09-28 | 51,240,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-03-31 to 2024-09-28 | 51,402,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-03-31 to 2024-09-28 | $21.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-03-31 to 2024-09-28 | $15.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2024-03-31 to 2024-09-28 | $75.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-09-28 | $299.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-28 | $955.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-28 | $2.53bn | us-gaap:Assets |
| Current liabilities | At period end2024-09-28 | $273.9m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2024-09-28 | $1.22bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-09-28 | $5.4m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-09-28 | $878.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000313143-24-000063. Last ingested by Listed: Nov 5, 2026, 11:22 ET. Listed shows no prices and gives no investment advice.